ADMA Biologics (ADMA) 10-K2013 FY Annual report

Filed: 28 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absolute, abstract, ASC, ASU, blue, Carryforward, CMV, compounded, Conference, construct, construction, cotton, deposit, divert, EU, eventual, expenditure, FDIC, forfeited, Georiga, GHA, heavily, HTGC, identification, immunecompromised, inconsistent, indeterminate, influenza, intrinsic, IPO, IVIG, launching, length, Marietta, milestone, moving, multiplied, nonemerging, nonqualified, oral, OTCQB, overallotment, Palivizumab, pneumoniae, preceding, preliminary, Ramsey, rat, reclassified, refinance, rental, Route, Serum, shortly, simplified, sky, stretch, symbol, Topic, tranche, underwriting, uplisting

Removed: acquired, applying, computing, consultant, diligence, effected, effecting, exercised, occurred, organized, participate, penny, personal, provision, Renshaw, Rodman, select, served, standing, taxable, vested, vote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ADMA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered

Public Accounting Firm

We consent to the incorporation by reference in the registration statement on Form S-8 filed by ADMA Biologics, Inc. of our report dated March 28, 2014, on our audits of the consolidated financial statements of ADMA Biologics, Inc. and Subsidiaries as of December 31, 2013 and 2012 and for the years then ended, included in this Annual Report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2013.

/s/ CohnReznick LLP

Roseland, New Jersey

March 28, 2014